Objective To investigate the safety and efficacy of paclitaxel or paclitaxel lipo-some for the treatment of breast cancer. Methods Eighty - four patients admitted to hospital from September 2010 to March 2012 were randomly divided into two groups, control group (n =42) and treatment group (n = 42). The control group was administered paclitaxel, and the treatment group was administered paclitaxel liposome. The clinical efficacy and the adverse effect in two groups were bserved and compared. Results The total efficiency rate in the treatment group was similar to the control group (P>0.05). The incidence rates of bone marrow suppression, gastrointestinal reactions, myocardial injury, abnormal liver function, and hair loss in the treatment group were similar to the control group (P>0.05). The incidence rates of rash, skin flushing, muscle aches, and difficulty breathing in the treatment group after treatment were significantly lower than those in the control group (P<0.05). Conclusion There is no difference in clinical efficacy of paclitaxel or paclitaxel liposomes in the treatment of breast cancer, but clinical application of paclitaxel liposomes can significantly alleviate adverse effect.%目的 探讨紫杉醇或紫杉醇酯质体治疗乳腺癌的安全性和有效性.方法 将2010年9月-2012年3月在本院诊治的84例乳腺癌患者随机分成2组:对照组42例,采用紫杉醇治疗方案；实验组42例,采用紫杉醇酯质体治疗方案.观察2组的临床疗效和毒副反应.结果 实验组患者的总有效率与对照组相比差异无统计学意义(P＞0.05)；实验组出现骨髓抑制、胃肠道反应、心肌损伤、肝功能异常、脱发等毒副反应的概率相比对照组差异无(P＞0.05),实验组出现皮疹、皮肤潮红、肌肉酸痛、呼吸困难等毒副反应的概率显著性低于对照组(P＜0.05).结论 紫杉醇或者紫杉醇酯质体治疗乳腺癌的临床疗效相似,但是紫杉醇酯质体的毒副作用更低.
展开▼
